Soaring rates of tuberculosis in children living in LondonMarch 21, 2002Rates of tuberculosis (TB) have risen 130 per cent in children living in London over the past decade, reports a study in Archives of Disease in Childhood. More TB is being diagnosed in 10 to 16 year olds than in any other childhood age group. Around 1 million cases of TB are diagnosed in children around the world every year. Data from the Public Health Laboratory Service Communicable Disease Surveillance Centre for 1982 to 1998 and the five yearly National Survey results for 1993 and 1998 were used to chart disease trends.
These show that rates of TB notifications in London among children aged 16 or younger fell between 1982 and 1988, since when they have risen every year, giving a cumulative rise of 130 per cent by 1998. In 1998 more than four out of 10 children with TB were Black African, compared with approximately one in four in 1993. One in five was from the Indian Subcontinent compared with one in two in 1993, and one in 10 were white compared with one four in the earlier survey. Almost one out of two affected children was born overseas in 1998, slightly fewer than in 1993, but most of these children developed TB within five years of entering the UK. The authors conclude that the high rate of infection among those born overseas emphasises the importance of immunisation. London health authorities use a mixture of universal and selective vaccination policies, but selective targeting can be difficult to implement, they say. British Medical Journal (BMJ) | |||||||||||||||||||||
|
Related Tuberculosis Current Events and Tuberculosis News Articles Scientists identify gene that may make humans more vulnerable to pulmonary tuberculosis Researchers from the Genome Institute of Singapore (GIS) and its collaborators have now identified for the first time a new gene that may confer susceptibility to pulmonary tuberculosis. Gene with probable role in human susceptibility to pulmonary tuberculosis identified A new gene that may confer susceptibility to pulmonary tuberculosis has been identified by Genome Institute of Singapore (GIS) researchers and their collaborators in The Netherlands, Indonesia, United Kingdom, and the Russian Federation. Groundbreaking, lifesaving TB vaccine a step closer Researchers at Aberystwyth University, following a number of years of investment by the Biotechnology and Biological Sciences Research Council (BBSRC), have licensed ground-breaking research to a non-profit product development partnership working to develop new, more effective vaccines against Tuberculosis (TB). This development will give hope that significantly better prevention and treatment of TB will be available within the next few years. 'Deadly dozen' reports diseases worsened by climate change Health experts from the Wildlife Conservation Society today released a report that lists 12 pathogens that could spread into new regions as a result of climate change, with potential impacts to both human and wildlife health and global economies. Disease diagnosis in just 15 minutes Testing for diseases such as cancer and multiple sclerosis could soon be as simple as using a pregnancy testing kit. New way to make malaria medicine also first step in finding new antibiotics University of Illinois microbiology professor William Metcalf and his collaborators have developed a way to mass-produce an antimalarial compound, potentially making the treatment of malaria less expensive. How to differentiate abdominal tuberculosis from lymphomas? The incidence of tuberculosis is increasing. Lymphadenopathy is the most common manifestation of abdominal tuberculosis and may, in up to 55% of cases without other evidence of abdominal involvement, be easily confused with lymphomas involving abdominal lymph nodes. New insights could lead to a better pneumococcal vaccine Discovery of a new, previously unknown mechanism of immunity suggests that there may be a better way to protect vulnerable children and adults against Streptococcus pneumoniae (pneumococcal) infection, say researchers at Children's Hospital Boston and Harvard School of Public Health (HSPH). Tuberculosis drug shows promise against latent bacteria A new study has shown that an investigational drug (R207910, currently in clinical trials against multi-drug resistant tuberculosis strains) is quite effective at killing latent bacteria. This revelation suggests that R207910 may lead to improved and shortened treatments for this globally prevalent disease. Novel tuberculosis vaccine in Germany in clinical phase For the first time in more than 80 years a promising live vaccine against tuberculosis has passed into the clinical phase in Germany: Since Monday of this week the new vaccine, which goes by the designation "VPM1002", has begun safety testing on volunteers in a Phase I clinical trial in Neuss, Germany. More Tuberculosis Current Events and Tuberculosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||